Luca Filippi

Prof. Luca Filippi

Local Health Authority - Latina, Santa Maria Goretti Hospital (Italy)
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2020 in Expert Review of Medical Devices
Verified
Journal Article
Closed access
Luca FilippiLuca Filippi
Luca Filippi
ACAgostino Chiaravalloti
Agostino Chiaravalloti
OSOrazio Schillaci
Orazio Schillaci
RCRoberto Cianni
Roberto Cianni
OBOreste Bagni
Oreste Bagni
Introduction: Theranostics is an emerging field in which diagnosis and specific targeted therapy are combined to achieve a personalized treatment approach to the patient. In nuclear medicine clinical practice, theranostics is often performed utilizing the same molecule labeled with two different radionuclides, one radionuclide for imaging and another for therapy. Areas covered: The authors review the clinical applications of different radiopharmaceuticals in the field of interest, including the well-established use of radioactive iodine in differentiated thyroid cancer, radiolabeled metaiodobenzylguanidine (MIBG) in neuroblastoma and the clinical impact of peptide radionuclide receptorial therapy (PRRT) in the management of neuroendocrine tumors. Furthermore, the more cutting-edge and recently introduced theranostic approaches will be reviewed, such as the radioligand therapy with 177Lu-prostate specific membrane antigen (PSMA) and targeted alpha therapy in castration resistant prostate cancer. Finally, the main applications of PET for the imaging of biomarkers suitable for the non-radionuclide targeted therapy will be covered. Expert opinion: Theranostics is envisaging a revolutionary clinical approach which is deeply connected with the concept of personalized medicine and ruled by a “patient-centered” vision. In this perspective, the theranostic applications will need well-trained specialists, capable to manage not only the technological aspects of the discipline, but also to deal with the more innovative oncological therapies in a multidisciplinary setting.

17 December 2008 in Journal of Nuclear Medicine
Verified
Journal Article
Open access
PDF file
FDFranca Dore
Franca Dore
Luca FilippiLuca Filippi
Luca Filippi
MBMatteo Biasotto
Matteo Biasotto
SCSilvia Chiandussi
Silvia Chiandussi
FCFabio Cavalli
Fabio Cavalli
Roberto Di LenardaRoberto Di Lenarda
Roberto Di Lenarda
Endovenous bisphosphonate therapy seems associated with osteonecrosis of the jaw. The aim of this study was to evaluate the additional diagnostic value of hybrid SPECT/CT in 99mTc-methylene diphosphonate 3-phase bone scintigraphy of osteonecrosis of the jaw in bisphosphonate-treated patients. Methods: We studied 15 patients (12 women and 3 men) with extraoral tumors affected by lytic bone metastases and multiple myeloma. All patients were previously treated with intravenous bisphosphonates (zoledronic acid) for 1–3 y, were negative for dental disease at clinical examination, and had suspected osteonecrosis of the jaw. All 15 patients underwent panoramic x-ray orthopantomography, CT or MRI (or both), microbiologic examination, 3-phase bone scintigraphy, and SPECT/CT of the maxillary region. Results: Three-phase bone-scintigraphy showed increased perfusion and an increased blood pool in 9 of 12 and 10 of 12 patients, respectively; at the metabolic phase, SPECT was positive in all patients and showed abnormal hyperactivity in the maxilla of 2 patients, in the mandible of 9 patients, and in both the mandible and the maxilla of 4 patients. Hybrid SPECT/CT was of particular value in 8 of 15 patients, allowing discrimination of the osteonecrotic core from nearby hyperactivity due to viable bone. Whole-body scintigraphy showed remote and multiple metastases in all patients. Orthopantomography showed nonspecific bone rarefaction in all patients but was not able to aid diagnosis of osteonecrosis of the jaw. CT and MRI showed anomalies in all symptomatic patients: CT was helpful in evaluating both cortical and trabecular bone aspects, and MRI was able to detect soft-tissue involvement but not cortical bone destruction. Conclusion: In appropriately selected oncology patients treated with bisphosphonates, an increased uptake of 99mTc-methylene diphosphonate in maxillary bones may suggest probable osteonecrosis of the jaw. In such cases, SPECT/CT may be of value in increasing the diagnostic accuracy of bone scanning, providing a precise functional anatomic correlation for the definition of the extent of disease.

12 June 2009 in Journal of Nuclear Medicine
Verified
Journal Article
Closed access
Luca FilippiLuca Filippi
Luca Filippi
LULuigi Uccioli
Luigi Uccioli
LGLaura Giurato
Laura Giurato
OSOrazio Schillaci
Orazio Schillaci
Our aim was to evaluate the role of SPECT/CT for the diagnosis of diabetic foot infection by labeled leukocytes. Seventeen patients with 19 clinically suspected sites of infection were included. After leukocyte labeling and administration, planar scans were acquired at 30 min, 4 h, and 24 h for 18 consecutive patients. SPECT/CT was obtained at 6 h. The final diagnosis was established by clinical follow-up (24 mo) in all cases and by bone biopsy for 14 sites. Leukocyte scanning was positive in 16 of 19 lesions and negative in 3. SPECT/CT changed the interpretation of the planar and SPECT images for 10 of 19 suspected sites (52.6%): it excluded osteomyelitis in 6 cases, revealed bone infection in 1 case, and revealed both bone and soft-tissue infection in 3 cases. The hybrid device did not significantly contribute to the evaluation of patients with negative scan results. SPECT/CT can be useful for a more accurate diagnosis of diabetic foot infection by labeled leukocyte imaging.

1 May 2005 in Nuclear Medicine Communications
Verified
Journal Article
Closed access
Luca FilippiLuca Filippi
Luca Filippi
CMCarlo Manni
Carlo Manni
MPMariangela Pierantozzi
Mariangela Pierantozzi
LBLivia Brusa
Livia Brusa
RDRoberta DANIELI
Roberta DANIELI
OSOrazio Schillaci
Orazio Schillaci
Background and aim 123I-FP-CIT SPECT has been successfully used to detect the loss of dopaminergic nigrostriatal neurons in Parkinson's disease at an early stage. In this study we evaluated the capacity of 123I-FP-CIT SPECT to assess bilateral dopamine transporter (DAT) loss in de-novo hemi-Parkinson's disease (PD) patients with one-sided clinical symptoms. Patients and methods Twenty-nine de-novo hemi-PD patients at an early stage (Hoehn & Yahr stage 1) and 18 gender and age matched healthy subjects were studied. SPECT imaging was always performed at 4 h post-injection. The ratios of striatal (S) to non-specific occipital (O) binding for the entire striatum (S/O), caudate nuclei (C/O), putamina (Pput/O), and the putamen to caudate nucleus index (Pput/C) were calculated in both the basal ganglia. Results In PD patients S/O, C/O and Pput/O ratio values contralateral to the clinically affected side were significantly lower (P<0.001) than in the control group (−38%, −34% and −42%, respectively). A significant reduction (P<0.001) of the striatal binding ratios was also found ipsilaterally (S/O, −31%; C/O, −28%; Pput/O, −33%). The Pput/C index was also bilaterally significantly reduced (P<0.01). DAT loss was significantly greater (P<0.001) in the contralateral than in the ipsilateral S; and putamen bilaterally presented a higher dopaminergic deficit than did caudate. Conclusion Our results indicate that semi-quantitative 123I-FP-CIT SPECT detects a bilateral dopaminergic deficit in early PD with unilateral symptoms and preclinical DAT loss in the ipsilateral striatal binding, corresponding to the side not yet affected by motor signs. Semi-quantitative analysis may thus be used to diagnose PD at an early stage as well as to identify individuals developing bilateral dopaminergic damage.

27 July 2012 in European Radiology
Verified
Journal Article
Closed access
PDF file
RCR. Cianni
R. Cianni
GPGiuseppe Pelle
Giuseppe Pelle
ENE. Notarianni
E. Notarianni
ASA. Saltarelli
A. Saltarelli
PRP. Rabuffi
P. Rabuffi
ECE. Cortesi
E. Cortesi

8 September 2005 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
OSOrazio Schillaci
Orazio Schillaci
MPMariangela Pierantozzi
Mariangela Pierantozzi
Luca FilippiLuca Filippi
Luca Filippi
CMCarlo Manni
Carlo Manni
LBLivia Brusa
Livia Brusa
PSPaolo Stanzione
Paolo Stanzione